Given that randomized controlled trials have shown a benefit of CRN in the management of mRCC when systemic treatment was IFN, CRN has remained a standard of care. With the advent of targeted ...

Researchers writing in JAMA Network Open report that for patients with metastatic clear cell renal cell carcinoma, removing the kidney and its primary tumor is not associated with improved overall ...

Please provide your email address to receive an email when new articles are posted on . Thirty-five percent of patients who received targeted therapy for renal cell carcinoma underwent cytoreductive ...

Please provide your email address to receive an email when new articles are posted on . Pretreatment with sunitinib followed by deferred cytoreductive nephrectomy did not improve 28-week ...

Metastatic renal cell carcinoma (RCC) has traditionally been associated with a poor prognosis with few effective treatments. In the multimodal treatment of metastatic RCC, cytoreductive nephrectomy ...

Although retrospective data supported a similar survival benefit for cytoreductive nephrectomy in the targeted therapy era as it did for the initial immunotherapy era (1992 to 2006), level 1 evidence ...

Renal cell carcinoma presents with metastatic disease in approximately 30% of patients at the time of diagnosis. Cytoreductive nephrectomy (CN) of the primary tumor in the face of metastatic disease ...

A pooled analysis compared survival among patients with metastatic renal cell carcinoma treated with cytoreductive nephrectomy and either targeted therapy or immunotherapy regimens utilizing ...

These randomized trials, however, were unable to provide insight into the mechanisms behind the survival benefit conferred by debulking nephrectomy, especially since survival was not dependent on the ...

Credit: Getty Images With effective modern systemic therapies for metastatic RCC, how cytoreductive nephrectomy affects quality of life has become an increasingly relevant question, according to ...

A Canadian study recently assessed 709 patients with intermediate- and high-risk synchronous mRCC with or without sarcomatoid features. Most patients had clear cell histology and were treated with ...

AUSTIN, Texas -- Cytoreductive nephrectomy improved overall survival (OS) by more than a year for patients with metastatic renal cell carcinoma (mRCC) with sarcomatoid or rhabdoid (S/R) ...